Option Care gets 75% of its revenues from chronic therapies and 25% from acute treatments, but its growth now looks ...

Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Beam is pursuing a long-term, staged development strategy for sickle cell disease that includes three “waves” of ...

Five years after the COVID-19 pandemic hit South Carolina and the U.S., it is still changing health care, from wastewater ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

The prespecified alpha level was 0.2. Results A total ... of all randomised patients who had received ≥1 dose of study drug. Safety analyses were grouped according to the treatment received.

The compound can then be delivered through injection, infusion ... reaching more treatment centres and patients,” Taylor outlined. Clarity announced in August that its phase 1/2a trial in ...

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

Gene Expression Unit, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Leuven, Belgium Background and aims: Infliximab is an effective treatment ... 1, prostaglandin-endoperoxide ...

It should be pointed out that dialysis is an efficient method of treatment of refractory ... to less than 6.5 mg/dL (1.62 mmol/L) and phosphorus level of 1.8 mg/dL (0.58 mmol/L). The patient was ...